Multiple Myeloma Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Multiple myeloma is a clonal malignancy of plasma cells — antibody-producing B-lymphocyte derivatives — that proliferate in the bone marrow and produce a monoclonal immunoglobulin (M-protein). Myeloma causes the classic 'CRAB' criteria: hyperCalcaemia, Renal impairment, Anaemia, and Bone disease (lytic lesions — the pathognomonic punched-out lytic lesions on X-ray, or diffuse osteoporosis from osteoclast activation by myeloma cells). It accounts for approximately 10% of all haematological malignancies and 1–2% of all cancers globally, with a median age at diagnosis of 69 years.

Multiple myeloma was until recently considered incurable — a relapsing-remitting disease managed through sequential lines of therapy. This narrative has been fundamentally challenged: with modern daratumumab-based quadruplet induction, high-dose melphalan + autologous stem cell transplant (ASCT) consolidation, and lenalidomide maintenance — a significant proportion of younger patients with favourable cytogenetics achieve MRD-negative complete remission sustained for 5–10+ years, raising the possibility of operational cure in a subset. MAIA trial (daratumumab + lenalidomide + dexamethasone for transplant-ineligible patients): median PFS 60.3 months — the longest in a Phase III frontline myeloma trial; OS benefit confirmed.

Key prognostic factors: cytogenetics (high-risk: del(17p), t(4;14), t(14;16), gain(1q21) — poor prognosis; standard risk: hyperdiploidy, t(11;14) — better prognosis); International Staging System (ISS) based on serum beta-2 microglobulin and albumin; LDH; performance status. ISS III and high-risk cytogenetics (R-ISS III) remain the most important adverse prognostic features guiding treatment intensity.

• Newly diagnosed transplant-eligible myeloma: The current standard in most guidelines: Daratumumab + bortezomib + lenalidomide + dexamethasone (Dara-VRd — PERSEUS trial): MRD negativity rate 75.2% at 12 months; superior PFS vs. VRd. Induction → ASCT → consolidation → maintenance: 4–6 cycles of Dara-VRd or D-VTd (daratumumab + bortezomib + thalidomide + dexamethasone — CASSIOPEIA trial: superior sCR rate and PFS vs. VTd) → high-dose melphalan (200 mg/m² for standard renal function; 140 mg/m² CKD) + ASCT → 2 cycles post-ASCT consolidation → lenalidomide maintenance until progression (MYELOMA XI: continuous lenalidomide maintenance significantly improves PFS vs. observation). Tandem ASCT (two sequential transplants): considered for high-risk cytogenetics (del17p, t4;14) — superior PFS in BMT CTN 0702 trial for certain high-risk subgroups. MRD assessment at multiple time points: pre-ASCT, day +100 post-ASCT — MRD negativity (10⁻⁵ by multiparameter flow or NGS) at CR predicts superior long-term outcomes.
• Newly diagnosed transplant-ineligible myeloma: Daratumumab + lenalidomide + dexamethasone (DRd — MAIA trial): PFS 60.3 months vs. 34.4 months Rd alone; OS benefit. Standard of care for fit transplant-ineligible patients. Daratumumab + bortezomib + melphalan + prednisone (D-VMP — ALCYONE trial): fixed-duration 9 cycles + daratumumab maintenance; superior PFS vs. VMP. Bortezomib + melphalan + prednisone (VMP): remains relevant where daratumumab access is limited. Frail patients: reduced-intensity Rd (lenalidomide 15 mg + dexamethasone 20 mg weekly); best supportive care with palliative intent.
• Relapsed/refractory myeloma: At relapse, re-induction with a regimen not containing the same class of agent (if prior exposure/resistance). Second-line options: Daratumumab + pomalidomide + dexamethasone (DPd); Isatuximab + carfilzomib + dexamethasone (Isa-Kd — IKEMA); Elotuzumab + pomalidomide + dexamethasone. For penta-refractory myeloma (refractory to proteasome inhibitor, IMiD, and CD38 antibody): BCMA-targeted therapy: Belantamab mafodotin (BLRM007 — antibody-drug conjugate — DREAMM-2 trial: 31% ORR in heavily pretreated patients, corneal toxicity — keratopathy monitoring); Teclistamab (BCMA × CD3 bispecific antibody — MajesTEC-1: 63% ORR, 39% sCR); Talquetamab (GPRC5D × CD3 bispecific); Idecabtagene vicleucel (ide-cel — bb2121 CAR-T — BCMA-targeted, KarMMa trial: 73% ORR, 33% CR); Ciltacabtagene autoleucel (cilta-cel — BCMA CAR-T — CARTITUDE-1: 98% ORR, 78% sCR — remarkable response depth in triple-class refractory myeloma).
• Smouldering multiple myeloma (SMM): High-risk SMM (2+ high-risk features): QUIREDEX/GEM trial: lenalidomide + dexamethasone reduced progression to symptomatic myeloma and significantly improved OS. High-risk SMM may benefit from early intervention in select patients — individualised decision with specialist. Standard/low-risk SMM: watch-and-wait with surveillance (serum protein electrophoresis, FLC, Hb, creatinine, calcium monitoring every 3–6 months).

Diagnostic workup for myeloma:

• Serum protein electrophoresis (SPEP) + immunofixation: M-protein identification and quantification; IgG, IgA, IgM, IgD, IgE, or light chain only (Bence Jones protein)
• Serum free light chains (FLC) + ratio: kappa/lambda ratio abnormality; critical for oligosecretory or light-chain-only myeloma; international staging and response criteria
• 24-hour urine protein electrophoresis + immunofixation: Bence Jones proteinuria (light chain urine M-protein)
• Bone marrow biopsy + aspirate: plasma cell percentage; morphology; immunophenotyping by flow cytometry; FISH (cytogenetics: del17p, t(4;14), t(14;16), gain(1q21) — mandatory for risk stratification)
• Whole-body low-dose CT (WBLDCT) or PET-CT: bone lesion survey — replaces plain skeletal survey (superior sensitivity); PET-CT adds functional assessment
• MRI whole spine and pelvis: mandatory when CRAB criteria include bone pain with negative WBLDCT; detects early diffuse marrow infiltration
• Bloods: FBC, β2-microglobulin (ISS staging), albumin (ISS), LDH, calcium, creatinine, eGFR, uric acid

Transplant eligibility:

• Eligible: age <70–75 (biological, not chronological — fitness-based); ECOG PS 0–2; adequate cardiac, renal, hepatic, pulmonary function; no comorbidity precluding high-dose melphalan
• Ineligible: age >75; ECOG 3–4; cardiac LVEF <40%; severe renal failure (eGFR <20); significant pulmonary or hepatic disease; frailty (IMWG Frailty Score)

Management of Multiple Myeloma Treatment is individualised based on disease severity, patient age, comorbidities, and patient values. The haematological and oncological team develops a personalised plan incorporating the following evidence-based treatment modalities:

• Conservative and lifestyle-based management: For many presentations, targeted lifestyle modification — including nutritional optimisation, graded physical activity, weight management, alcohol and smoking cessation — forms the foundation of care. Regular specialist monitoring and patient self-management education enable early detection of deterioration and empower patients to actively participate in their treatment.
• Pharmacological therapy: Evidence-based drug therapy tailored to disease mechanism and individual patient profile forms the pharmacological backbone. First-line agents are selected per current international guidelines, with treatment escalated to second-line or combination therapy for inadequate responders. Regular monitoring ensures therapeutic efficacy and detects adverse effects early.
• Procedural and interventional approaches: Where pharmacological management is insufficient or specific structural or functional abnormalities are identified, minimally invasive or interventional procedures are considered. These are performed by experienced haematological and oncological specialists at accredited facilities with appropriate pre-procedure preparation and post-procedure monitoring protocols.
• Surgical treatment: Surgery is indicated for patients with advanced disease, complications, or conditions unresponsive to medical management. Modern surgical approaches include laparoscopic, robotic-assisted, and image-guided techniques that minimise operative morbidity and accelerate recovery. Surgical decisions are made following multidisciplinary discussion and informed consent.
• Multidisciplinary team (MDT) care: Complex presentations are managed through an MDT integrating expertise from relevant specialties — haematological and oncological medicine, radiology, physiotherapy, nutrition, psychology, and palliative care as appropriate. MDT-driven care demonstrably improves outcomes for complex conditions. Patient and family involvement in MDT planning ensures alignment with individual values.
• Emerging and clinical trial options: Access to investigational treatments through clinical trials at specialist centres offers patients with refractory or high-risk presentations the opportunity to access next-generation therapies under systematic monitoring. Trial eligibility is assessed as part of the MDT plan.

• Daratumumab transforms outcomes across all lines: Daratumumab (anti-CD38 monoclonal antibody) has dramatically improved PFS and OS when added to backbone regimens at every line of therapy. MAIA (frontline transplant-ineligible, DRd): median PFS 60.3 months vs. 34.4 months (Rd). CASSIOPEIA (frontline transplant-eligible, D-VTd): sCR rate 28.9% vs. 20.3% (VTd) at post-consolidation. CANDOR (relapsed/refractory, DKd): median PFS 28.6 vs. 15.2 months (Kd). Daratumumab's mechanism is multifaceted: direct antimyeloma cytotoxicity (CDC, ADCC); immunomodulation (depletion of CD38+ immunosuppressive cells — regulatory T-cells, myeloid-derived suppressor cells — thereby restoring anti-tumour immune responses). Isatuximab (anti-CD38 — distinct epitope from daratumumab, not cross-resistant) provides an alternative CD38 antibody for daratumumab-exposed patients.
• ASCT consolidation still improves outcomes in the daratumumab era: Despite outstanding response rates with quadruplet induction, ASCT consolidation further deepens responses — converting partial responses to complete responses, and complete responses to MRD negativity. Long-term IFM 2009 data and FORTE trial confirm ASCT superiority in PFS vs. chemotherapy alone, even in the era of novel agents. MRD negativity rates post-ASCT with daratumumab-based induction approach 70–80% — offering the best current chance of very long-duration remission in myeloma.
• BCMA-targeted CAR-T — transformative responses in relapsed/refractory disease: Ciltacabtagene autoleucel (cilta-cel — BCMA CAR-T, JNJ): CARTITUDE-1 — 98% ORR; 78% stringent CR; 24-month PFS 60.6%; responses durable. CARTITUDE-4 (earlier relapse setting): superior PFS vs. standard of care (pomalidomide or VMP). For patients who have failed multiple lines of therapy — including proteasome inhibitors, IMiDs, and anti-CD38 — BCMA CAR-T achieves response rates and depth unattainable with any prior therapy, with durable remissions in a significant proportion.

• Peripheral neuropathy — bortezomib and thalidomide: Bortezomib causes peripheral neuropathy in 30–40% — predominantly sensory (numbness, tingling), occasionally painful. Risk reduction: subcutaneous administration (vs. IV) reduces neuropathy incidence from 44% to 24% without compromising efficacy (Moreau 2011 trial). Weekly bortezomib dosing (vs. twice weekly) also reduces neuropathy. Thalidomide causes cumulative dose-dependent peripheral neuropathy — avoid above 100 mg/day for prolonged periods; neuropathy may be irreversible. Carfilzomib has significantly less neurotoxicity than bortezomib — preferred for patients with pre-existing neuropathy. Lenalidomide: minimal neurotoxicity — preferred IMiD in neuropathy-prone patients.
• Cardiac toxicity of carfilzomib: Carfilzomib (next-generation proteasome inhibitor) — superior anti-myeloma activity vs. bortezomib but associated with cardiac adverse events: hypertension (25–35%), cardiac failure (4–8%), cardiac ischaemia (2–5%), dyspnoea (25%). Baseline and periodic cardiac evaluation (ECG, ECHO) required. Carfilzomib is avoided or used with caution in patients with pre-existing significant cardiac disease. ENDEAVOR trial (carfilzomib vs. bortezomib in relapsed myeloma): carfilzomib superior PFS and OS but higher cardiac event rate.
• Infections — daratumumab and immunoparesis: Myeloma itself causes immunoparesis (suppression of normal immunoglobulin production) — infectious susceptibility. Daratumumab depletes CD38+ regulatory T-cells and NK cells — further immunosuppression. VZV (varicella-zoster virus) reactivation: antiviral prophylaxis (aciclovir 400 mg BD or valaciclovir 500 mg OD) mandatory throughout treatment. PJP prophylaxis (co-trimoxazole) for patients on bortezomib or high-dose dexamethasone. COVID-19 and influenza: high mortality risk — vaccination recommended (though attenuated response on treatment). IVIG replacement for patients with recurrent infections and hypogammaglobulinaemia (IgG <4 g/L).
• BCMA CAR-T and bispecific antibody toxicities: Cytokine release syndrome (CRS): occurs in 95%+ patients receiving BCMA CAR-T; grade 3+ in 4–10%. Managed with tocilizumab ± corticosteroids. Neurotoxicity/ICANS: less common than CD19 CAR-T — 17–21%. Movement and neurocognitive treatment-emergent adverse events (MNT): unique to cilta-cel — Parkinsonism-like syndrome in 3–5% — mechanism unclear. Infection: prolonged B-cell aplasia and hypogammaglobulinaemia after BCMA CAR-T — IVIG replacement for 12+ months; PJP prophylaxis. Teclistamab bispecific: CRS rate 72% (grade 3+ <1%); infections (40% grade 3–4) — prolonged immunosuppression; subcutaneous administration facilitating outpatient management.

Treatment response monitoring: Following initiation of Multiple Myeloma Treatment, clinical response is assessed at 4–12 weeks. Objective parameters (laboratory values, imaging, functional assessments) and symptom scores are tracked; treatment is adjusted based on response and tolerability.

Regular specialist review: Ongoing management requires specialist appointments every 3–6 months once stable, with more frequent reviews during treatment initiation, dose adjustment, or when complications arise. Each visit includes clinical assessment, medication review, and complication screening.

Long-term monitoring: Annual comprehensive review including laboratory investigations, imaging as indicated, quality-of-life assessment, and screening for disease-related complications. Lifelong healthy lifestyle behaviours and regular check-ins with primary care complement specialist follow-up to ensure continuity of care and early detection of any deterioration.

Multiple myeloma treatment is among the most expensive in oncology — particularly novel agents (daratumumab, carfilzomib, BCMA CAR-T). India offers significant cost advantages through generic proteasome inhibitors and biosimilar anti-CD38 antibodies:

• India: Generic bortezomib (Velcade generic — Bortec, Bortronex): USD 300–600/cycle vs. USD 2,000–5,000 branded in USA. Lenalidomide generic (Lenalid, Lenangio): USD 100–300/month vs. USD 15,000–20,000 branded Revlimid in USA. Thalidomide (Thalix generic): USD 20–50/month. Daratumumab (Darzalex): USD 2,000–5,000/infusion in India (branded — biosimilar not yet available in India); USD 7,000–10,000/infusion in USA. Carfilzomib (Kyprolis branded): USD 3,000–6,000/cycle. Autologous HSCT for myeloma: USD 15,000–35,000 in India vs. USD 200,000–500,000 in USA. Pomalidomide (Pomalyst generic): USD 500–1,000/month in India vs. USD 20,000–25,000 branded in USA. Bisphosphonate (zoledronic acid generic): USD 30–80/infusion. BCMA CAR-T (ide-cel, cilta-cel): not currently available in India — globally USD 400,000–500,000 per infusion. Teclistamab (Tecvayli): not available in India. Major myeloma treatment centres: Tata Memorial Hospital (Mumbai), AIIMS (New Delhi), CMC Vellore, Apollo Hospitals, Max Healthcare.
• Thailand: Bortezomib (branded): USD 1,000–2,000/cycle. Lenalidomide: USD 2,000–5,000/month. Daratumumab: USD 4,000–8,000/infusion. ASCT: USD 40,000–80,000.
• United Kingdom (NHS): Bortezomib (NICE TA311), lenalidomide maintenance (NICE TA587), daratumumab-based regimens (multiple NICE TAs), carfilzomib combinations, isatuximab, pomalidomide — all funded on NHS for approved indications at specialist haematology centres. BCMA CAR-T (ide-cel — NHS England CDF; cilta-cel pending NICE final guidance 2025). Bisphosphonate (zoledronic acid): free on NHS.
• United States: Daratumumab (Darzalex Faspro SC — per injection): USD 7,000–10,000. Carfilzomib (Kyprolis per cycle): USD 10,000–20,000. Lenalidomide (Revlimid — branded, before generic availability): USD 20,000–25,000/month; generic: USD 1,000–5,000/month. Pomalidomide (Pomalyst): USD 25,000/month. Idecabtagene vicleucel (Abecma CAR-T): USD 419,500. Ciltacabtagene autoleucel (Carvykti): USD 465,000. Annual myeloma treatment cost (induction + maintenance): USD 100,000–500,000/year.

Alternative or complementary approaches may be considered for patients unsuitable for standard Multiple Myeloma Treatment, preferring less intensive treatment, or seeking additional options alongside conventional care:

• Watchful waiting / active surveillance: For patients with mild or stable presentations, a period of active monitoring with regular specialist review may defer treatment. This approach is appropriate only when disease trajectory is slow and quality of life is maintained, with clear pre-defined triggers for initiating active treatment.
• Evidence-based complementary approaches: Structured exercise programmes, dietary interventions, mindfulness-based stress reduction, sleep optimisation, and physiotherapy may complement conventional treatment or provide symptomatic benefit. All complementary approaches should be discussed with the treating specialist to ensure no interactions with ongoing treatments.
• Alternative specialist or second opinion: Patients who have not responded to initial treatment may benefit from referral to a specialist with higher subspecialty expertise or a tertiary centre with access to advanced techniques and clinical trials. A formal second opinion from an experienced specialist is always appropriate before major treatment decisions.
• Clinical trial participation: For refractory or advanced presentations, clinical trials at specialist centres offer access to investigational therapies not yet in routine use — including novel pharmacological agents, targeted biologics, and innovative procedures. Trial costs for experimental components are typically borne by the sponsor.
• Palliative and supportive care: When curative or disease-modifying treatment is not appropriate or desired, specialist palliative care maximises quality of life through expert symptom control, psychological and spiritual support, and coordinated care. Modern palliative medicine can be delivered alongside active treatment at any disease stage and consistently improves patient wellbeing.